(Reuters Health) – According to a study of 15 emergency departments, patients over age 80 who are admitted to intensive care are often not asked their opinion about admission.
(Reuters Health) – Monitoring growth can serve as an early warning for many childhood diseases, but a lack of consensus on how tracking should work and what to look for may mean diagnosis is delayed for some and wrong for others, a recent research review suggests.
(Reuters Health) – Toddlers who already speak two languages are better than their peers at a particular kind of problem solving that requires knowing when it’s okay to change the rules, according to a new study.
LONDON (Reuters) – More use of vaccines would reduce the need to use antibiotics and help fight the rise of drug-resistant superbug infections, according to a British government-commissioned review of the threat.
BRASILIA (Reuters) – Brazilian health authorities believe three adults died last year of suspected complications related to the Zika virus, the Health Ministry said on Thursday.
PRAIA/LONDON (Reuters) – Florzinha Amado is eight months pregnant and trying to stay calm about whether the Zika virus infection she contracted at 21 weeks could have harmed her unborn child.
(Reuters) – Incyte Corp said it would discontinue some of the trials testing its already approved blood cancer drug, Jakafi, after the treatment’s effectiveness was found to be insufficient.
LUANDA (Reuters) – A yellow fever outbreak in Angola has killed 37 people since December with eight new cases reported in the last 24 hours, the country’s national director of health Adelaide de Carvalho said late on Wednesday.
ZURICH (Reuters) – The European Medicines Agency (EMA) has accepted an application to review Sandoz’s biosimilar to Amgen’s EU-licensed Neulasta (pegfilgrastim), a recombinant human granulocyte colony-stimulating factor, Sandoz parent Novartis said on Thursday.
(Reuters) – Walgreens Boots Alliance Inc, the largest U.S. drugstore chain, threatened to terminate its relationship with Theranos Inc unless the blood-testing company quickly fixes the problems found by federal inspectors at its laboratory in California, the Wall Street Journal reported.